Elevated levels of homocysteine predict cardiovascular death, nonfatal myocardial infarction, and symptomatic bypass graft disease at 2-year follow-up following coronary artery bypass surgery

Preventive Cardiology

Volumn 11, Issue 2, 2008, Pages 95-99

  Shammas, Nicolas W ^a,b   Dippel, Eric J ^a   Jerin, Michael ^a   Toth, Peter P ^a   Kapalis, Matthew ^a   Reddy, Mythri ^a   Harb, Harb ^a  

^a MIDWEST CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b Cardiovascular Medicine Davenport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CREATINE KINASE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; AMINO ACID BLOOD LEVEL; ANGINA PECTORIS; ARTERY DISEASE; ARTICLE; BODY MASS; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG USE; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOMOCYSTEINE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MATURITY ONSET DIABETES MELLITUS; MORTALITY; PREDICTION; PRIORITY JOURNAL; SMOKING; TRANSIENT ISCHEMIC ATTACK; VEIN GRAFT DISEASE; BLOOD; GRAFT OCCLUSION; MIDDLE AGED; PREDICTION AND FORECASTING; TREATMENT OUTCOME;

AGED; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 45149101063     PISSN: 1520037X     EISSN: 17517141     Source Type: Journal    
DOI: 10.1111/j.1751-7141.2008.08293.x     Document Type: Article

References (27)

1. Goldman S, Copeland J, Moritz T, et al. Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study. Circulation. 1989;80(5):1190-1197.
2. Lawrie GM, Lie JT, Morris GC Jr, et al. Vein graft patency and intimal proliferation after aortocoronary bypass: Early and long-term angiopathologic correlations. Am J Cardiol. 1976;38(7):856-862.
3. Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation. 1991;83(5):1526-1533.
4. Angelini GD. Saphenous vein graft failure: Etiologic considerations and strategies for prevention. Curr Opin Cardiol. 1992;7(6):939-944.
5. Batayias GE, Barboriak JJ, Korns ME, et al. The spectrum of pathologic changes in aortocoronary saphenous vein grafts. Circulation. 1977;56(3 suppl):II18-II22.
6. Paz MA, Lupon J, Bosch X, et al. Predictors of early saphenous vein aortocoronary bypass graft occlusion. The GESIC Study Group. Ann Thorac Surg. 1993;56(5):1101-1106.
7. Moor E, Blomback M, Silveira A, et al. Haemostatic function in patients undergoing coronary artery bypass grafting: Peroperative perturbations and relations to saphenous vein graft closure. Thromb Res. 2000;98(1):39-49.
8. Rifon J, Paramo JA, Panizo C, et al. The increase of plasminogen activator inhibitor activity is associated with graft occlusion in patients undergoing aorto-coronary bypass surgery. Br J Haematol. 1997;99(2):262-267.
9. Dotani MI, Elnicki DM, Jain AC, et al. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol. 2000;86(10):1128-1130, A6.
10. Zampoulakis JD, Kyriakousi AA, Poralis KA, et al. Lipoprotein(a) is related to the extent of lesions in the coronary vasculature and to unstable coronary syndromes. Clin Cardiol. 2000;23(12):895-900.
11. Agewall S, Fagerberg B. Lipoprotein(a) was an independent predictor for major coronary events in treated hypertensive men. Clin Cardiol. 2002;25(6):287-290.
12. Rath M, Niendorf A, Reblin T, et al. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989;9(5):579-592.
13. Hoff HF, Beck GJ, Skibinski CI, et al. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation. 1988;77:1238-1244.
14. Burke AP, Fonseca V, Kolodgie F, et al. Increased serum homocysteine and sudden death resulting from coronary atherosclerosis with fibrous plaques. Arterioscler Thromb Vasc Biol. 2002;22:1936-1941.
15. Klerk M, Verhoef P, Clarke R, et al; MTHFR Studies Collaboration Group. MTHFR 677C. T polymorphism and risk of coronary heart disease: A meta-analysis. JAMA. 2002;288:2023-2031.
16. Nurk E, Tell GS, Vollset SE, et al. Plasma total homocysteine and hospitalizations for cardiovascular disease: The Hordaland Homocysteine Study. Arch Intern Med. 2002;162(12):1374-1381.
17. Ridker PM, Manson JE, Buring JE, et al. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA. 1999;281(19):1817-1821.
18. Ariyo A, Hennekens CH, Stampfer MJ, et al. Lipoprotein (a), lipids, aspirin, and risk of myocardial infarction in the Physician's Health Study. J Cardiovasc Risk. 1998;5(4):273-278.
19. Eritsland J, Arnesen H, Seljeflot I, et al. Influence of serum lipoprotein(a) and homocyst(e)ine levels on graft patency after coronary artery bypass grafting. Am J Cardiol. 1994;74(11):1099-1102.
20. Iwama Y, Mokuno H, Yokoi H, et al. Elevated levels of plasma homocysteine related to saphenous vein graft disease after coronary artery bypass graft surgery. J Cardiol. 1998;32(6):357-362.
21. Iwama Y, Mokuno H, Watanabe Y, et al. Relationship between plasma homocysteine levels and saphenous vein graft disease after coronary artery bypass grafts. Jpn Heart J. 2001;42(5):553-562.
22. Harris M, Shammas NW, Jerin M. Elevated levels of low-density lipoprotein cholesterol, homocysteine, and lipoprotein(a) are associated with the occurrence of symptomatic bypass graft disease 1 year following coronary artery bypass graft surgery. Prev Cardiol. 2004;7:106-108.
23. Maron BA, Loscalzo J. Should hyperhomocysteinemia be treated in patients with atherosclerotic disease? Curr Atheroscler Rep. 2007;9:375-383.
24. Ridker PM, Rifai N, Pfeffer MA, et al; Cholesterol And Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839-844.
25. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-1577.
26. Bønaa KH, Njølstad I, Ueland PM, et al; NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578-1588.
27. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA. 2004;291(5):565-575.